Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Pulmonary And Respiratory Medicine

Cancer Research

Show all topics

DOI

10.1016/j.annonc.2020.08.2100

License

CC-BY-NC-ND

Other Formats

PDF